Emerging landscape in psoriasis management: From topical application to targeting biomolecules

Rapalli, Vamshi Krishna; Singhvi, Gautam; Dubey, Sunil Kumar; Gupta, Gaurav; Chellappan, Dinesh Kumar; Dua, Kamal

doi:10.1016/j.biopha.2018.06.136

Cited by 73 publications

(39 citation statements)

References 41 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…These results indicate a role for miRNAs in lung tissues and plasma as molecular predictors of lung cancer development and aggressiveness and have theoretical and clinical implication for lung cancer management Rapalli et al, 2018;Singh et al, 2017).…”

Section: Development Of Renin-angiotensin-aldosterone/mas Receptormentioning

confidence: 70%

“…In fact, miR‐21 is upregulated in diverse tumors and plays a potential role in the angiogenesis of cancers (Zhao et al, ). These results indicate a role for miRNAs in lung tissues and plasma as molecular predictors of lung cancer development and aggressiveness and have theoretical and clinical implication for lung cancer management (Gupta et al, ; Rapalli et al, ; Singh et al, ).…”

Section: Development Of Renin–angiotensin–aldosterone/mas Receptor Axismentioning

confidence: 88%

See 1 more Smart Citation

Angiotensin II‐induced micro RNA‐21 culprit for non‐small‐cell lung adenocarcinoma

Luan

Liu

Shi³

2019

Drug Development Research

View full text Add to dashboard Cite

Lung cancer is among the most complicated cancers, with an estimated 1.6 million deaths each year for both men and women. However, the proportion of lung cancer patients in developing nations has increased from 31% to 49.9% in the last two decades. There are two main subtypes of lung cancer, small‐cell lung carcinoma and non‐small‐cell lung carcinoma (NSCLC), accounting for 15% and 85% of all lung cancer, respectively. Adenocarcinoma is the most common type of lung cancer in smokers and nonsmokers in men and women regardless of their age. Chemicals in cigarette smoke and nicotine enter our bloodstream and can then affect the entire body and finally lead to the activation of several important, pro‐survival signaling pathways. The biologically active peptide of RAAS on overstimulation enhance Ang II mediates cell proliferation, fibrosis and inflammatory effects via AT1 receptor. Very few studies highlight the diagnostic and therapeutic potential of miRNAs with the EGFR‐regulated miRNA‐21.

show abstract

Section: Development Of Renin-angiotensin-aldosterone/mas Receptormentioning

confidence: 70%

Section: Development Of Renin–angiotensin–aldosterone/mas Receptor Axismentioning

confidence: 88%

Angiotensin II‐induced micro RNA‐21 culprit for non‐small‐cell lung adenocarcinoma

Luan

Liu

Shi³

2019

Drug Development Research

View full text Add to dashboard Cite

show abstract

“…Despite the huge burden of major respiratory disease, there is a lack of effective treatments that could limit the disease onset and/or disease progression (Dua, Chellappan, et al, ; Dua, Gupta, Chellappan, Shukla, & Hansbro, ; Dua, Rapalli, et al, ; Dua, Shukla, de Jesus Andreoli Pinto, & Hansbro, ; Rapalli et al, ). Thus, extensive research into potentially novel therapeutics is urgently required.…”

Section: Introductionmentioning

confidence: 99%

The potential of siRNA based drug delivery in respiratory disorders: Recent advances and progress

Dua

Wadhwa

Singhvi

et al. 2019

Drug Development Research

Self Cite

141

View full text Add to dashboard Cite

Lung diseases are the leading cause of mortality worldwide. The currently available therapies are not sufficient, leading to the urgent need for new therapies with sustained anti‐inflammatory effects. Small/short or silencing interfering RNA (siRNA) has potential therapeutic implications through post‐transcriptional downregulation of the target gene expression. siRNA is essential in gene regulation, so is more favorable over other gene therapies due to its small size, high specificity, potency, and no or low immune response. In chronic respiratory diseases, local and targeted delivery of siRNA is achieved via inhalation. The effectual delivery can be attained by the generation of aerosols via inhalers and nebulizers, which overcomes anatomical barriers, alveolar macrophage clearance and mucociliary clearance. In this review, we discuss the different siRNA nanocarrier systems for chronic respiratory diseases, for safe and effective delivery. siRNA mediated pro‐inflammatory gene or miRNA targeting approach can be a useful approach in combating chronic respiratory inflammatory conditions and thus providing sustained drug delivery, reduced therapeutic dose, and improved patient compliance. This review will be of high relevance to the formulation, biological and translational scientists working in the area of respiratory diseases.

show abstract

“…Psoriasis treatment includes topical therapy, systemic therapy, phototherapy, and biological therapy. However, topical therapy is mostly preferred for mild to moderate psoriasis in which corticosteroids, vitamin D analogues, vitamin A retinoids are used as monotherapy or in combination . As a part of combination therapy, betamethasone valerate and tazarotene are preferred to provide improved therapeutic efficacy with lesser side effects .…”

Section: Introductionmentioning

confidence: 99%

Stability indicating liquid chromatographic method for simultaneous quantification of betamethasone valerate and tazarotene in in vitro and ex vivo studies of complex nanoformulation

Rapalli

Singhvi

Gorantla

et al. 2019

J of Separation Science

Self Cite

View full text Add to dashboard Cite

Low‐potency corticosteroid betamethasone valerate and vitamin‐A tazarotene are used in combination for effective treatment of psoriasis. There is no robust high‐performance liquid chromatography analytical technique available for simultaneous estimation of betamethasone valerate and tazarotene in conventional and nanocarriers based formulations. A simple, accurate, robust isocratic high‐performance liquid chromatography method was developed for simultaneous estimation of betamethasone valerate and tazarotene in topical pharmaceutical formulations. The developed method was validated as per the regulatory guidelines. The validated method was linear over the concentration range of 150–6000 ng/mL (r2 > 0.999) at 239 nm wavelength. Limits of detection and quantification of two analytes were 50 and 150 ng/mL, respectively. The %relative standard deviation for intraday and interday precision was less than 2%. The method was also evaluated in the presence of forced degradation conditions. The developed method was successfully applied for in vitro and ex vivo drug release studies of in‐house designed nanoformulations.

show abstract

Emerging landscape in psoriasis management: From topical application to targeting biomolecules

Cited by 73 publications

References 41 publications

Angiotensin II‐induced micro RNA‐21 culprit for non‐small‐cell lung adenocarcinoma

Angiotensin II‐induced micro RNA‐21 culprit for non‐small‐cell lung adenocarcinoma

The potential of siRNA based drug delivery in respiratory disorders: Recent advances and progress

Stability indicating liquid chromatographic method for simultaneous quantification of betamethasone valerate and tazarotene in in vitro and ex vivo studies of complex nanoformulation

Contact Info

Product

Resources

About